Switzerland is slipping further down the European rankings when it comes to access to new innovative medicines: according to IQVIA’s EFPIA WAIT Indicator 2024, Switzerland has dropped another place, falling from sixth to seventh. It is particularly alarming that only around half as many new innovative medicines are reimbursed as standard via the specialty list as in Germany – and the trend is downward [1].
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Chronic pain
Nano-ECS modulator Adezunap improves therapy success
- Psoriasis and PsA
Biologics, oral peptide and trivalent nanobody – current results and trends
- Cancer in Europe: facts and analysis
New Health Policy Report published
- Gastrointestinal complaints
PPI regulation under the microscope
- Wound management: clinical diagnostics
Assessing the risk of infection – from the ABCDE to the TILI score
- Study report
Digital patient education for atrial fibrillation shows measurable effects
- New practice guideline for fibromyalgia syndrome
Good times, bad times
- IBDmatters - Synergy effects for IBD pathways